Cite
HARVARD Citation
Tak, P. et al. (2013). Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Annals of the rheumatic diseases. 72 (3), pp. 337-344. [Online].